Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.
CAR gains from rising demand for short-term vehicle rentals, but geopolitical risks, low liquidity and lack of dividend cloud its long-term outlook.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 18 | $2,743.06 | $2,861.82 | $118.76 | 4.33% |
| YA Yinka Akinsola Blue Trust Inc. | 562 | $82,292.5 | $89,363.62 | $7,071.12 | 8.59% |
Jeff Ameen Spire Wealth Management | 5 | $729.25 | $798.9 | $69.65 | 9.55% |
| MD Michelle Dubey Yousif Capital Management LLC | 6,189 | $1.34M | $995,871.99 | -$345,997.99 | -25.78% |
Joseph Castro Nuveen LLC | 33,482 | $2.61M | $5.34M | $2.73M | 104.92% |
| Transportation Infrastructure Industry | Industrials Sector | Brian J. Choi CEO | NASDAQ (NGS) Exchange | 053774105 CUSIP |
| US Country | 17,000 Employees | 21 Dec 2023 Last Dividend | 5 Sep 2006 Last Split | 12 Jan 1990 IPO Date |
Avis Budget Group, Inc. operates as a comprehensive provider of mobility solutions, catering to both business and consumer needs across various geographical realms including the Americas, Europe, the Middle East and Africa, Asia, and Australasia. With its roots tracing back to 1946 and a rebranding from Cendant Corporation in September 2006, this entity has grown into a formidable platoon in the mobility services domain, headquartered in Parsippany, New Jersey. Through its diverse portfolio of brands — Avis, Budget, Zipcar, and several others — the company is strategically positioned across different market segments, from premium commercial and leisure travel to value-conscious consumer segments.
Avis Budget Group, Inc. boasts a wide range of mobility solutions and ancillary products and services, addressing the varied necessities of its clientele. Here's an overview of their primary offerings: